ERG and cancer: For example, loss of CEACAM1 [44], SOX9 [45], phospho-mTOR [46], and CEBPA [47], as well as deletion at chromosome 3p13 [30] (displayed a prognostic role only in ERG-positive cancers, while altered expression of SFRP4 [48], GATA2 [49], hnRNPA1 [50], NBS1 [51], FOXP2 [52], MTC02 [53], BCAR1 [54], p16 [55], YB-1 [56], MSH6 [57], and GGH [58] were prognostically relevant in ERG-negative tumors only.